Jentadueto Xr
A linagliptin and metformin tablet for type 2 diabetes. Metformin cuts liver glucose output; linagliptin boosts insulin release after meals.
- Category
- Diabetes Management
- Active ingredients
- Linagliptin · Metformin
- Route
- Oral use
- Form
- Tablet
- Strengths
- 5mg + 1000mg
Prescription and consultation requirements for Jentadueto Xr vary by destination and are determined by the fulfilment partner.
Jentadueto Xr details
- Condition
- Type 2 Diabetes Mellitus
- Alternative names
- linagliptin, metformin
- Therapeutic class
- DPP-4 Inhibitor, Biguanide Combination
- Pharmacological class
- Antidiabetic Combination
- Contraindications
- severe renal impairment; acute metabolic acidosis; diabetic ketoacidosis
- Minor side effects
- diarrhoea; nausea; headache
- Moderate side effects
- stuffy nose; metallic taste; flatulence
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Boehringer Ingelheim
- Onset Time
- 1–2 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Contrast Media; Alcohol; Rifampin
- Age restrictions
- Approved for adults.
Serious side effects
lactic acidosis, requires immediate medical attention; acute pancreatitis, requires immediate medical attention
Patient summary
A linagliptin and metformin tablet for type 2 diabetes. Metformin cuts liver glucose output; linagliptin boosts insulin release after meals.
Mechanism of action
Metformin lowers liver glucose output while linagliptin increases active inkretin hormones to optimise insulin output.
Pregnancy and breastfeeding
Pregnancy: Use if benefit outweighs risk. Avoid in late term. Breastfeeding: Not recommended.